Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01994889 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 441
- Enrollment target
NCT01994889 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 441 participants.
The verdict
NCT01994889, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 441 participants
- Enrollment target
Study Summary
This Phase 3 study will investigate the efficacy, safety and tolerability of an oral daily dose of 20 mg or 80 mg tafamidis meglumine capsules compared to placebo in subjects with either transthyretin genetic variants or wild-type transthyretin resulting in amyloid cardiomyopathy.
Interventions
- DRUG Placebo
- DRUG Tafamidis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 441 participants |
| Start Date | 2013-12-09 |
| Est. Completion | 2018-02-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01994889
The ClinicalTrials.gov registry entry for NCT01994889 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 441 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01994889 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01994889 about?
NCT01994889 is a clinical study titled "Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy". This Phase 3 study will investigate the efficacy, safety and tolerability of an oral daily dose of 20 mg or 80 mg tafamidis meglumine capsules compared to placebo in subjects with either transthyretin genetic variants or wild-type transthyretin resulting in amyloid cardiomyopathy.
What is the current status of trial NCT01994889?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 441 participants. The study started on 2013-12-09. Estimated completion is 2018-02-07.
What interventions are being tested in trial NCT01994889?
The interventions under investigation include: Placebo (DRUG), Tafamidis (DRUG).
Who is sponsoring clinical trial NCT01994889?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.